245 related articles for article (PubMed ID: 33782605)
1. Gain-of-function variants in SYK cause immune dysregulation and systemic inflammation in humans and mice.
Wang L; Aschenbrenner D; Zeng Z; Cao X; Mayr D; Mehta M; Capitani M; Warner N; Pan J; Wang L; Li Q; Zuo T; Cohen-Kedar S; Lu J; Ardy RC; Mulder DJ; Dissanayake D; Peng K; Huang Z; Li X; Wang Y; Wang X; Li S; Bullers S; Gammage AN; Warnatz K; Schiefer AI; Krivan G; Goda V; Kahr WHA; Lemaire M; ; Lu CY; Siddiqui I; Surette MG; Kotlarz D; Engelhardt KR; Griffin HR; Rottapel R; Decaluwe H; Laxer RM; Proietti M; Hambleton S; Elcombe S; Guo CH; Grimbacher B; Dotan I; Ng SC; Freeman SA; Snapper SB; Klein C; Boztug K; Huang Y; Li D; Uhlig HH; Muise AM
Nat Genet; 2021 Apr; 53(4):500-510. PubMed ID: 33782605
[TBL] [Abstract][Full Text] [Related]
2. Spleen tyrosine kinase inhibition blocks airway constriction and protects from Th2-induced airway inflammation and remodeling.
Tabeling C; Herbert J; Hocke AC; Lamb DJ; Wollin SL; Erb KJ; Boiarina E; Movassagh H; Scheffel J; Doehn JM; Hippenstiel S; Maurer M; Gounni AS; Kuebler WM; Suttorp N; Witzenrath M
Allergy; 2017 Jul; 72(7):1061-1072. PubMed ID: 27906453
[TBL] [Abstract][Full Text] [Related]
3. Genetic and Pharmacological Dissection of the Role of Spleen Tyrosine Kinase (Syk) in Intestinal Inflammation and Immune Dysfunction in Inflammatory Bowel Diseases.
Biagioli M; Mencarelli A; Carino A; Cipriani S; Marchianò S; Fiorucci C; Donini A; Graziosi L; Baldelli F; Distrutti E; Costantino G; Fiorucci S
Inflamm Bowel Dis; 2017 Dec; 24(1):123-135. PubMed ID: 29272492
[TBL] [Abstract][Full Text] [Related]
4. Cerdulatinib Pharmacodynamics and Relationships to Tumor Response Following Oral Dosing in Patients with Relapsed/Refractory B-cell Malignancies.
Coffey GP; Feng J; Betz A; Pandey A; Birrell M; Leeds JM; Der K; Kadri S; Lu P; Segal J; Wang YL; Michelson G; Curnutte JT; Conley PB
Clin Cancer Res; 2019 Feb; 25(4):1174-1184. PubMed ID: 30333224
[TBL] [Abstract][Full Text] [Related]
5. The Novel Oral Syk Inhibitor, Bl1002494, Protects Mice From Arterial Thrombosis and Thromboinflammatory Brain Infarction.
van Eeuwijk JM; Stegner D; Lamb DJ; Kraft P; Beck S; Thielmann I; Kiefer F; Walzog B; Stoll G; Nieswandt B
Arterioscler Thromb Vasc Biol; 2016 Jun; 36(6):1247-53. PubMed ID: 27102960
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic inhibition of spleen tyrosine kinase in inflammatory macrophages using PLGA nanoparticles for the treatment of non-alcoholic steatohepatitis.
Kurniawan DW; Jajoriya AK; Dhawan G; Mishra D; Argemi J; Bataller R; Storm G; Mishra DP; Prakash J; Bansal R
J Control Release; 2018 Oct; 288():227-238. PubMed ID: 30219279
[TBL] [Abstract][Full Text] [Related]
7. SYK inhibition targets acute myeloid leukemia stem cells by blocking their oxidative metabolism.
Polak A; Bialopiotrowicz E; Krzymieniewska B; Wozniak J; Stojak M; Cybulska M; Kaniuga E; Mikula M; Jablonska E; Gorniak P; Noyszewska-Kania M; Szydlowski M; Piechna K; Piwocka K; Bugajski L; Lech-Maranda E; Barankiewicz J; Kolkowska-Lesniak A; Patkowska E; Glodkowska-Mrowka E; Baran N; Juszczynski P
Cell Death Dis; 2020 Nov; 11(11):956. PubMed ID: 33159047
[TBL] [Abstract][Full Text] [Related]
8. Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis.
Coffey G; DeGuzman F; Inagaki M; Pak Y; Delaney SM; Ives D; Betz A; Jia ZJ; Pandey A; Baker D; Hollenbach SJ; Phillips DR; Sinha U
J Pharmacol Exp Ther; 2012 Feb; 340(2):350-9. PubMed ID: 22040680
[TBL] [Abstract][Full Text] [Related]
9. Selective inhibition of spleen tyrosine kinase (SYK) with a novel orally bioavailable small molecule inhibitor, RO9021, impinges on various innate and adaptive immune responses: implications for SYK inhibitors in autoimmune disease therapy.
Liao C; Hsu J; Kim Y; Hu DQ; Xu D; Zhang J; Pashine A; Menke J; Whittard T; Romero N; Truitt T; Slade M; Lukacs C; Hermann J; Zhou M; Lucas M; Narula S; DeMartino J; Tan SL
Arthritis Res Ther; 2013 Oct; 15(5):R146. PubMed ID: 24286216
[TBL] [Abstract][Full Text] [Related]
10. Downregulation of the Syk Signaling Pathway in Intestinal Dendritic Cells Is Sufficient To Induce Dendritic Cells That Inhibit Colitis.
Hang L; Blum AM; Kumar S; Urban JF; Mitreva M; Geary TG; Jardim A; Stevenson MM; Lowell CA; Weinstock JV
J Immunol; 2016 Oct; 197(7):2948-57. PubMed ID: 27559049
[TBL] [Abstract][Full Text] [Related]
11. TAS05567, a Novel Potent and Selective Spleen Tyrosine Kinase Inhibitor, Abrogates Immunoglobulin-Mediated Autoimmune and Allergic Reactions in Rodent Models.
Hayashi H; Kaneko R; Demizu S; Akasaka D; Tayama M; Harada T; Irie H; Ogino Y; Fujino N; Sasaki E
J Pharmacol Exp Ther; 2018 Jul; 366(1):84-95. PubMed ID: 29728446
[TBL] [Abstract][Full Text] [Related]
12. Unperturbed Immune Function despite Mutation of C-Terminal Tyrosines in Syk Previously Implicated in Signaling and Activity Regulation.
Weis V; Königsberger S; Amler S; Wienands J; Kiefer F
Mol Cell Biol; 2017 Nov; 37(21):. PubMed ID: 28760774
[TBL] [Abstract][Full Text] [Related]
13. Second-Generation SYK Inhibitor Entospletinib Ameliorates Fully Established Inflammation and Bone Destruction in the Cherubism Mouse Model.
Yoshimoto T; Hayashi T; Kondo T; Kittaka M; Reichenberger EJ; Ueki Y
J Bone Miner Res; 2018 Aug; 33(8):1513-1519. PubMed ID: 29669173
[TBL] [Abstract][Full Text] [Related]
14. C-Type Lectin-Like Receptor 2 Suppresses AKT Signaling and Invasive Activities of Gastric Cancer Cells by Blocking Expression of Phosphoinositide 3-Kinase Subunits.
Wang L; Yin J; Wang X; Shao M; Duan F; Wu W; Peng P; Jin J; Tang Y; Ruan Y; Sun Y; Gu J
Gastroenterology; 2016 May; 150(5):1183-1195.e16. PubMed ID: 26855187
[TBL] [Abstract][Full Text] [Related]
15. Involvement of B Cells, Immunoglobulins, and Syk in the Pathogenesis of Abdominal Aortic Aneurysm.
Furusho A; Aoki H; Ohno-Urabe S; Nishihara M; Hirakata S; Nishida N; Ito S; Hayashi M; Imaizumi T; Hiromatsu S; Akashi H; Tanaka H; Fukumoto Y
J Am Heart Assoc; 2018 Mar; 7(6):. PubMed ID: 29545260
[TBL] [Abstract][Full Text] [Related]
16. Generation of a novel system for studying spleen tyrosine kinase function in macrophages and B cells.
Miller AL; Zhang C; Shokat KM; Lowell CA
J Immunol; 2009 Jan; 182(2):988-98. PubMed ID: 19124742
[TBL] [Abstract][Full Text] [Related]
17. Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling.
Myklebust JH; Brody J; Kohrt HE; Kolstad A; Czerwinski DK; Wälchli S; Green MR; Trøen G; Liestøl K; Beiske K; Houot R; Delabie J; Alizadeh AA; Irish JM; Levy R
Blood; 2017 Feb; 129(6):759-770. PubMed ID: 28011673
[TBL] [Abstract][Full Text] [Related]
18. The Syk Tyrosine Kinase Is Required for Skin Inflammation in an In Vivo Mouse Model of Epidermolysis Bullosa Acquisita.
Németh T; Virtic O; Sitaru C; Mócsai A
J Invest Dermatol; 2017 Oct; 137(10):2131-2139. PubMed ID: 28576735
[TBL] [Abstract][Full Text] [Related]
19. Genetic deficiency of Syk protects mice from autoantibody-induced arthritis.
Jakus Z; Simon E; Balázs B; Mócsai A
Arthritis Rheum; 2010 Jul; 62(7):1899-910. PubMed ID: 20201079
[TBL] [Abstract][Full Text] [Related]
20. SYK inhibition and response prediction in diffuse large B-cell lymphoma.
Cheng S; Coffey G; Zhang XH; Shaknovich R; Song Z; Lu P; Pandey A; Melnick AM; Sinha U; Wang YL
Blood; 2011 Dec; 118(24):6342-52. PubMed ID: 22025527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
